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The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40e60% of mel-
anoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and
Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive
metastatic melanoma. We report a case of metastatic amelanotic melanoma with unknown primary
cancer as the initial presentation. The patient presented with neutrophilic septal panniculitis 1 week
after vemurafenib treatment, which is a rare cutaneous toxicity of BRAF inhibitor. We also review the
current literature on management of BRAF inhibitor-related adverse skin effects.
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The treatment of metastatic melanoma is challenging. BRAF gene
mutation is found in 40e60% ofmelanoma cases, themost common
being the V600E mutation. Vemurafenib was approved by the Food
and Drug Administration in 2011 as target therapy for the treat-
ment with BRAF V600 mutation-positive metastatic melanoma. In
this report, we present a case of metastatic amelanotic melanoma
with unknown primary cancer as the initial presentation. The pa-
tient presented with neutrophilic septal panniculitis 1 week after
vemurafenib treatment, which is a rare cutaneous toxicity of BRAFy have no ﬁnancial or non-
atter or materials discussed
gery, Department of Surgery,
Section 4, Taiwan Boulevard,
al Association. Published by Elseviinhibitor (BRAFi). We also review the current literature on man-
agement of BRAFi-related adverse skin effects.
Case Report
The patient was a 75-year-old woman, a retired farmer, with a
medical history of hypertension under regular control. She was
diagnosed as having metastatic melanoma with unknown primary
tumor, cTxNxM1, by excision of right axillary lymphadenopathy.
Serum tumor marker surveys, including carcinoembryonic antigen,
squamous cell carcinoma antigen, cancer antigen 153, cancer anti-
gen 125, and alpha-fetoprotein, were all within normal limits. The
pathology report of right axillary lymphadenopathy revealed inﬁl-
trating epithelioid malignancy with solid growth pattern, abundant
cytoplasm, enlarged and vesicular nuclei, prominent nucleoli, and
briskmitotic activity (Figure 1A). The immunohistochemical studies
showed negative reactivity for cytokeratin AE1/AE3, inhibin, calre-
tinin, leukocyte common antigen, CD34, and CD30. Expressions of S-
100 protein, HMB-45 (humanmelanomablack-45; Figure 1B andD),
Melan-A (Figure 1C), and MiTF-1 (microphthalmia-associateder Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1 (A) Pathology shows inﬁltrating epithelioid malignancywith solid growth pattern, abundant cytoplasm, enlarged and vesicular nuclei, prominent nucleoli, and brisk mitotic
activity (hematoxylin and eosin; original magniﬁcation, 400). (B) Positivity for HMB-45 of tumor cells (original magniﬁcation, 200). (C) Positivity for Melan-A of tumor cells
(original magniﬁcation, 200). (D) Positivity for MiTF-1 of tumor cells (original magniﬁcation, 200). (E) Pathology shows mainly septal pannuculitis with red blood cells extrava-
sation (hematoxylin and eosin; original magniﬁcation40). (F) Inﬂammatory cell inﬁltrates along septa and focal lobular area of subcutaneous fat, which is predominantly composed
of neutrophils (hematoxylin and eosin; original magniﬁcation, 400). HMB-45 ¼ human melanoma black-45; MiTF-1 ¼ microphthalmia-associated transcription factor-1.
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was metastatic malignant amelanotic epithelioid melanoma. On
physical examination, no obvious primary skin tumor was noted.
Whole-body positron emission tomography showed metastases to
the right axillary area, right supraclavicular area, right shoulder, the
mediastinum, and bilateral pulmonary hili (Figure 2B). She also had
progressive dysphagia and dyspnea, which are probably related to
themetastaseswith initial upper airway compression. The presence
of a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene
point mutation at codon 600 from valine to glutamate was
conﬁrmed by the LightCycler HybProbe real-time polymerase chain
reaction assay for the right axillary lymphadenopathy specimen
(Figure 2A). Under a diagnosis of metastatic melanoma with BRAF
V600E mutation, she received oral vemurafenib (720 mg daily), a
speciﬁc inhibitor of mutant BRAF.
About 1 week under vemurafenib treatment, she noticed
several painful skin lesions on her abdomen and bilateral lowerlimbs. She denied fever, arthralgia, or other symptoms of
discomfort. On physical examination, there were several tender
erythematous subcutaneous nodules with inﬁltration over the
abdomen and four limbs (Figure 2D and E). Laboratory in-
vestigations showed the following results: white blood cell
count, 10,600/cumm; hemoglobin, 12.5 g/dL; platelet count,
380,000/cumm; other serum chemistry, urinalysis, and serologic
evaluations of thyroid and renal functions yielded results that
were all within the normal ranges. Mildly elevated levels of C-
reactive protein level (3.99 mg/dL) and erythrocyte sedimenta-
tion rate of 94 mm in the 1st hour were noted. Complement 3
and 4 levels, antinuclear antibody titers, antineutrophil cyto-
plasmic antibody titers, and procalcitonin level were assessed to
rule out other possible causes for the erythema nodosum (EN),
and all values were entirely within normal limits. Results of her
serologic test for rapid plasma reagin and treponema pallidum
hemagglutination were negative. Her chest roentgenogram
Figure 2 (A) The presence of BRAF gene point mutation at codon 600 from valine to glutamate was conﬁrmed by the LightCycler HybProbe real-time polymerase chain reaction
assay for the right axillary lymphadenopathy specimen. (B) Whole-body positron emission tomography (PET) prior to treatment revealed metastases to right axillary area, right
supraclavicular area, right shoulder, the mediastinum, and bilateral pulmonary hili. (C) Whole-body PET 8 weeks after treatment showed complete remission of radioactivity. (D)
There were several tender erythematous subcutaneous nodules with inﬁltration over abdomen. (E) There was a tender erythematous subcutaneous nodule over right thigh.
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diagnosis included EN, deep morphea, subcutaneous Sweet's
syndrome, lupus panniculitis, infectious panniculitis, factitious
panniculitis, melanoma metastases, or other cause of pan-
niculitis, and thus we performed skin biopsy of the tender
subcutaneous nodules 1 week after the ﬁrst skin lesion occurred.
The pathology of skin biopsy revealed inﬂammatory cell in-
ﬁltrates along the septa and focal lobular area of subcutaneous
fat, which was predominantly composed of neutrophils with red
blood cells extravasation (Figure 1E and F). Direct immunoﬂuo-
rescence showed negative ﬁndings for immunoglobulin G,
immunoglobulin M, and complement 3. They were negative for
polarizable material, and special stains for microorganisms
(including acid-fast stain, periodic acid-Schiff stain, and Gram
stain) did not reveal any microorganisms. The ﬁnal diagnosis
was vemurafenib-associated neutrophilic panniculitis.
Vemurafenib was tapered to 480 mg daily. In addition, pred-
nisolone (5mg daily) and Celebrex (25mg daily) were prescribed to
treat the skin lesions. After 5 weeks of treatment, her skin lesions
subsided, and no new skin lesion was noted. We tried to escalate
vermurafenib to 720 mg daily, but similar tender subcutaneous
nodules recurred. Thus, we kept vemurafenib dose at 480 mg daily,
and no more new skin lesions were noted after that. After 8 weeks
of treatment, we performed a reevaluation using whole-body
positron emission tomography, which showed remission of radio-
activity (Figure 2C). Under the impression of metastatic melanoma
with complete remission, the patient received continued treatment
with reduced dose of vemurafenib (480 mg daily).Discussion
BRAF gene mutation is found in 40e60% of melanoma cases, the
most common being the V600E mutation. BRAF V600E mutation
leads to activation of the mitogen-activated protein kinase (MAPK)
pathway.1,2 According to the literature, BRAF gene mutation ac-
counts for < 20% of melanoma cases in Taiwan.3 In addition, the
prevalence rate of metastatic melanoma of unknown primary
origin, which is without an identiﬁable primary lesion, is very low
(<5%).4 Our patient represented a case of metastatic melanoma
with unknown primary origin and conﬁrmed BRAF V600E muta-
tion. The treatment of metastatic melanoma is challenging. The
new-generation BRAFi, vemurafenib, has become the standard of
care for American Joint Committee on Cancer stage IV metastatic
melanoma with positive BRAF V600E mutation. Vemurafenib was
approved by the Food and Drug Administration in 2011 as a target
therapy for the treatment of BRAF V600 mutation-positive meta-
static melanoma.5 Studies conducted on the treatment efﬁcacy of
this agent have shown signiﬁcant improvements in overall survival
and progression-free survival.1,5 The most frequent adverse skin
effects include secondary tumors, such as skin papillomas, squa-
mous cell carcinomas, and secondary melanoma.6 Furthermore,
handefoot skin reactions, acantholytic dyskeratoses, milia, pruri-
tus, and alopecia may occur.6
The amelanotic melanoma represents 2e8% of all melanomas.
These melanomas have a unique appearance and present a great
diagnostic challenge to dermatologists.7 In addition, the prevalence
rate of melanoma is lower in Asians, and themost common subtype
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unknown primary cancer, which may be reasonable owing to the
difﬁculty of performing clinical diagnosis of amelanotic melanoma.
BRAFi is associated with a number of adverse skin effects.
Vemurafenib-associated adverse effects are more common in
elderly and comorbid patients.8 EN-like panniculitis appears to be a
rarely reported adverse effect of vemurafenib. Therewere ~30 cases
reported as vemurafenib-associated neutrophilic panniculitis, but
all cases occurred in Western countries, which may be related to
the prevalence rate of melanoma.6,9 Other extracutaneous side ef-
fects include fever (31%), fatigue, arthralgia (44%), photosensitivity,
central scotoma, myalgia, and conjunctivitis.6,10 The median time to
presentation of EN-like skin lesions is 8 weeks, ranging from 7 days
to 16 months. In 69% of those patients, the cutaneous side effects
occur within the ﬁrst 3 months of therapy.6 The most commonly
involved body sites are lower legs, followed by thighs, hands,
gluteal area, trunk, and even dissemination.6 According to the
current literature, another BRAFi, dabrafenib, and theMEK inhibitor
trametinib, have similar reported side effects.6 In our patient, no
systemic symptoms and signs were noted. In addition, the skin
lesions developed just 1 week after initiation of vemurafenib
treatment, and complete remission of metastatic melanoma was
observed after 8 weeks of treatment. Zimmer et al11 reported that
80% of studied patients with neutrophilic panniculitis showed at
least a partial response to therapy. Whether these skin manifesta-
tions could be a surrogate marker for response to BRAFi therapy,
analogous to the epidermal growth factor inhibitors, requires
further investigation.11
The pathomechanisms of BRAFi-induced EN-like skin lesions
have not been elucidated yet. It was proposed that these symptoms
might be part of a systemic inﬂammatory reaction to the drug or
the melanoma.10 One hypothesis links these side effects to a par-
adoxical activation of the MAPK pathway in wild-type BRAF
cells.12,13 In another hypothesis, the complex effects of BRAFi on
pathways might deregulate neutrophil migration and might lead to
neutrophil-related side effects.6 Sweet's syndrome following
vemurafenib therapy for recurrent cholangiocarcinoma has been
reported.14
Acquired drug toxicity and drug resistance are key challenges
when using BRAFi. These side effects are usually managed by dose
interruption and/or a reduction, leading to concerns about the
ability to adequately inhibit the MAPK pathway.8 In a study with 16
cases, most cases (75%) exhibited EN-like lesions during BRAFi
therapy and were treated symptomatically with nonsteroidal anti-
inﬂammatory drugs and topical glucocorticosteroids. Systemic
glucocorticosteroids were used for only a small portion (12.5%) of
patients with severe symptoms and widespread lesions followed
by a tapered regimen.6 A temporary interruption of BRAFi treat-
ment or dosage reduction was necessary in some patients (56%),
and BRAFi treatment was then continued at a lower dose in most of
the patients without recurrence.6 Some cases (56%) were main-
tained on the same BRAFi dosage, and spontaneous resolution of
the skin side effects occurred.6 Two reported cases of successful
retreatment with vemurafenib or dabrafenib provide evidence of
this phenomenon.15 Data from the BRIM-3 (BRAF Inhibitor inMelanoma-3) trial showed that many vemurafenib toxicities that
developed after several weeks of treatment were resolved by reg-
ular breaks in treatment, and thus an intermittent regimen may
enhance drug tolerability.5 Dooley et al8 also proposed an inter-
mittent dosing regimen as an alternative to dose reduction/termi-
nation for patients with drug toxicities, and 50% patients showed
an improvement in tolerability. In our patient, escalation of
vemurafenib dosage resulted in recurrence of EN-like skin lesions.
Thus, skin toxicity of BRAFi may be dosage dependent. The minimal
required dosagewas 480mg daily maintained in our patient, which
is consistent with previous studies.8,16
We report a case of metastatic amelanotic melanomawith BRAFi
V600E mutation and unknown primary cancer as the initial pre-
sentation. The patient presented with neutrophilic panniculitis 1
week after treatment with vemurafenib. These lesions subsided
after reduction of dosage with low-dose steroid and nonsteroid
anti-inﬂammatory drug use. To the best of our knowledge, this is
the ﬁrst reported case of neutrophilic panniculitis associated with
vemurafenib for melanoma treatment in Taiwan.
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